Tiziana's Phase II Study in Non-Active, Secondary Progressive Multiple Sclerosis скачать в хорошем качестве

Tiziana's Phase II Study in Non-Active, Secondary Progressive Multiple Sclerosis

Tiziana Life Sciences' (NASDAQ: TLSA) Chief Medical Officer Matthew W. Davis, MD, joins us to announce the planned start of a Phase II study in non-active secondary progressive multiple sclerosis. The study is expected to begin in 3Q:23. Other Videos in the Series: Tiziana Reports Improvements in Expanded Access SPMS Patients -    • Tiziana Reports Improvements in Expanded A...   Tiziana to Submit IND for Alzheimer's Disease -    • Tiziana to Submit IND for Alzheimer's Disease   Tiziana's Phase II Study in Non-Active, Secondary Progressive Multiple Sclerosis -    • Tiziana's Phase II Study in Non-Active, Se...   SPMS Clinical Improvement with Tiziana's Foralumab -    • SPMS Clinical Improvement with Tiziana's F...   Tiziana's Phase II SPMS Trial Planned for 3Q:23 -    • Tiziana's Phase II SPMS Trial Planned for ...   Tiziana's Foralumab a Potential Treatment for Long COVID -    • Tiziana's Foralumab a Potential Treatment ...   Fireside Chat with Tiziana's Dr. Davis -    • Tiziana Life Sciences Fireside Chat with C...   Supporting Material: Latest Research Note: https://scr.zacks.com/news/news-detai...